References


Alsina M, Richardson PGG, Schlossman RL, et al. Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8531


Jakubowiak AJ, Dytfeld D, Griffith KA, et al. Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8543

Al-Hamadani M, Go RS, Use of stem cell transplantation (SCT) as initial therapy in multiple myeloma (MM) and impact of sociodemographic factors in the era of novel agents: Analysis of 137,409 patients using the National Cancer Data Base (NCDB). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8580

Song KW, Dimopoulos MA, Weisel KC, et al. Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM 1 LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8583

Richardson PGG, Hofmeister CC, Siegel DSD, et al. MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8584

Matous J, Siegel DSD, Duong HK, et al. MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8585

Siegel DSD, Richardson PGG, Vij R, et al. Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8588

Alahamdi MS, Tay J, Early versus late treatment for smoldering (asymptomatic) multiple myeloma: A systematic review. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8593


Hilger JD, Berenson JR, Klein LM, et al. A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8598

Berenson JR, Hilger JD, Dichmann R, et al. Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8599

Kassim A, McDuffie JS, Mosse CA et al. Minimal residual disease (MRD) status pre- and post- high-dose therapy/autologous stem (HDC/ASCT) cell transplantation for multiple myeloma (MM) in the era of novel agents. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8605


Lee HC, Shah JJ, Orlowski RZ Novel Approaches to Treatment of Double-Refractory Multiple Myeloma ASCO.org/edbook. 2013;e302(e306)

Reece, D Update on the Initial Therapy of Multiple Myeloma ASCO.org/edbook. 2013;e307(e312)

San-Miguel JF, Paiva B, Gutierrez NC New Tools for Diagnosis and Monitoring of Multiple Myeloma ASCO.org/edbook. 2013;e313(e318)